-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Alopexx, Inc. (ALPX) Plans to Raise $15 Million in October 6th IPO
Alopexx, Inc. (ALPX) Plans to Raise $15 Million in October 6th IPO
Alopexx, Inc. (ALPX) plans to raise $15 million in an IPO on Thursday, October 6th, IPO Scoop reports. The company will be issuing 3,000,000 shares at $5.00 per share.
The company has a market-cap of $39.2 million.
ThinkEquity served as the underwriter for the IPO.
Alopexx, Inc. provided the following description of their company for its IPO: "We are a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). That target has been found on an expanding number of pathogens. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management's assessment that the broad-spectrum potential of our therapeutics will allow them to be used for the prevention, treatment, and mitigation of a wide range of infections. In a first-in-man trial, our vaccine candidate, AV0328, has been shown to be well tolerated with no serious adverse events observed. It was noted to induce protective antibodies against all PNAG-expressing pathogens tested. We believe our vaccine's broad-spectrum potential will allow it to be used for the long-term prevention of a wide range of infections, including pneumococcal pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), meningitis and sexually transmitted diseases. Similarly, our fully human monoclonal antibody, F598, which also targets PNAG, has been shown to be well tolerated and no serious adverse events were noted in phase 1 and pilot phase 2 trials. We believe it can provide immediate protection lasting 2-3 months. We seek to establish F598 as the standard of care for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units (ICU). Utilization of these therapeutics also has potential applicability beyond infectious diseases, including treatment of neurological conditions and cognitive decline due to inflammation. Note: Net loss is for the year ended Dec. 31, 2021. **Note: As of June 30, 2022, we had an accumulated deficit of $5.99 million. Alopexx says that it has three officers and no employees before the IPO, according to the prospectus. (Note: Alopexx increased the size of its IPO to 3.0 million shares, up from 2.5 million shares, and cut the price to $5.00, the bottom of its previous $5.00-to-$7.00 range, to raise $15 million (same estimate as before), according to an S-1/A filing dated Sept. 6, 2022. Alopexx disclosed its IPO terms – 2.5 million shares at $5.00 to $7.00 to raise $15 million – in an S-1/A filing dated Aug. 24, 2022. Alopexx filed an S-1/A dated April 20, 2022, disclosing that its proposed stock symbol is "ALPX". On March 4, 2022, Alopexx filed its S-1. The company filed confidential IPO documents with the SEC on Jan. 7, 2022.) ".
Alopexx, Inc. was founded in 2006 and has 0 employees. The company is located at 186 Alewife Brook Pkwy #1068 Cambridge, Massachusetts 02138 and can be reached via phone at (617) 780-1598 or on the web at
Receive News & Ratings for Alopexx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alopexx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
Alopexx, Inc. (ALPX) plans to raise $15 million in an IPO on Thursday, October 6th, IPO Scoop reports. The company will be issuing 3,000,000 shares at $5.00 per share.
据IPO Scoop报道,Alopexx公司(Alopexx,Inc.)计划在10月6日(星期四)首次公开募股(IPO)中筹集1,500万美元。该公司将以每股5美元的价格发行300万股股票。
The company has a market-cap of $39.2 million.
该公司的市值为3920万美元。
ThinkEquity served as the underwriter for the IPO.
ThinkEquity担任此次IPO的承销商。
Alopexx, Inc. provided the following description of their company for its IPO: "We are a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). That target has been found on an expanding number of pathogens. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management's assessment that the broad-spectrum potential of our therapeutics will allow them to be used for the prevention, treatment, and mitigation of a wide range of infections. In a first-in-man trial, our vaccine candidate, AV0328, has been shown to be well tolerated with no serious adverse events observed. It was noted to induce protective antibodies against all PNAG-expressing pathogens tested. We believe our vaccine's broad-spectrum potential will allow it to be used for the long-term prevention of a wide range of infections, including pneumococcal pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), meningitis and sexually transmitted diseases. Similarly, our fully human monoclonal antibody, F598, which also targets PNAG, has been shown to be well tolerated and no serious adverse events were noted in phase 1 and pilot phase 2 trials. We believe it can provide immediate protection lasting 2-3 months. We seek to establish F598 as the standard of care for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units (ICU). Utilization of these therapeutics also has potential applicability beyond infectious diseases, including treatment of neurological conditions and cognitive decline due to inflammation. Note: Net loss is for the year ended Dec. 31, 2021. **Note: As of June 30, 2022, we had an accumulated deficit of $5.99 million. Alopexx says that it has three officers and no employees before the IPO, according to the prospectus. (Note: Alopexx increased the size of its IPO to 3.0 million shares, up from 2.5 million shares, and cut the price to $5.00, the bottom of its previous $5.00-to-$7.00 range, to raise $15 million (same estimate as before), according to an S-1/A filing dated Sept. 6, 2022. Alopexx disclosed its IPO terms – 2.5 million shares at $5.00 to $7.00 to raise $15 million – in an S-1/A filing dated Aug. 24, 2022. Alopexx filed an S-1/A dated April 20, 2022, disclosing that its proposed stock symbol is "ALPX". On March 4, 2022, Alopexx filed its S-1. The company filed confidential IPO documents with the SEC on Jan. 7, 2022.) ".
Alopexx公司在首次公开募股时介绍了他们的公司:“我们是一家临床阶段的生物技术公司,开发新型免疫疗法,用于预防、治疗和缓解细菌、真菌和寄生虫感染,这些感染表达抗原靶向聚N-乙酰氨基葡萄糖(PNAG)。在越来越多的病原体上发现了这个靶点。虽然我们疗法的安全性和有效性的最终决定将由FDA和其他卫生当局决定,但我们管理层的评估是,我们疗法的广谱潜力将使它们能够用于预防、治疗和缓解各种感染。在第一次人体试验中,我们的候选疫苗AV0328被证明耐受性良好,没有观察到严重的不良事件。人们注意到,它可以诱导针对所有被测试的表达PNAG的病原体的保护性抗体。我们相信,我们的疫苗的广谱潜力将使其能够用于长期预防各种感染,包括肺炎球菌肺炎、耐甲氧西林金黄色葡萄球菌(MRSA)、脑膜炎和性传播疾病。同样,我们的全人单抗F598也针对PNAG,已被证明具有良好的耐受性,在第一阶段和第二阶段的试点试验中没有发现严重的不良反应。我们相信它可以提供持续2-3个月的即时保护。我们寻求将F598确立为预防和改善入院重症监护病房(ICU)患者的革兰氏阴性和革兰氏阳性细菌感染以及表达PNAG的微生物的真菌感染的护理标准。这些疗法的应用也具有超越传染病的潜在用途。, 包括治疗神经系统疾病和因炎症而导致的认知能力下降。注:净亏损为截至2021年12月31日的年度。**注:截至2022年6月30日,我们的累计赤字为599万美元。根据招股说明书,Alopexx表示,在IPO之前,该公司有三名高管,没有员工。(注:根据日期为9月1日的S-1/A文件,Alopexx将IPO规模从250万股提高到300万股,并将发行价下调至5.00美元,这是之前5.00美元至7.00美元区间的底部,以筹集1,500万美元(与之前的估计相同)。6,2022年。Alopexx在日期为2022年8月24日的S-1/A文件中披露了其IPO条款-250万股,价格在5美元至7美元之间,筹资1,500万美元。Alopexx提交了一份日期为2022年4月20日的S-1/A文件,披露其拟议的股票代码为“ALPX”。2022年3月4日,Alopexx提交了S-1。该公司于2022年1月7日向美国证券交易委员会提交了机密的上市文件。
Alopexx, Inc. was founded in 2006 and has 0 employees. The company is located at 186 Alewife Brook Pkwy #1068 Cambridge, Massachusetts 02138 and can be reached via phone at (617) 780-1598 or on the web at
Alopexx,Inc.成立于2006年,现有员工0名。该公司位于马萨诸塞州02138,坎布里奇市,地址为:阿莱费斯布鲁克Pkwy#1068,电话:(6177801598)
Receive News & Ratings for Alopexx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alopexx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收Alopexx Inc.的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收Alopexx Inc.和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧